News Related to Nonarteritic Anterior Ischemic Optic Neuropathy

Related coverage linked through entity extraction aliases.

Ocular Therapeutix Axpaxli Succeeds in Phase 3 Trial; Oculis Plans Q2 2026 Readouts

Mar 04, 2026

Ocular Therapeutix's Axpaxli outperformed low-dose Eylea in a Phase 3 trial for wet AMD, while Oculis Holding reported narrowed Q4 losses and expects Phase 3 trial readouts for OCS-01 in Q2 2026.

Semaglutide Linked to Doubled Risk of Rare Optic Neuropathy in Veterans Study

Dec 22, 2025

A nationwide study of US veterans with type 2 diabetes found semaglutide initiation more than doubled the risk of nonarteritic anterior ischemic optic neuropathy compared to SGLT2 inhibitors, though absolute risk remained low at 0.29%.